The Healthy Aging Company Appoints Modulus Biotech as Its Exclusive Worldwide Partnering and Licensing Representative for ALF5755
A first-in-class REG3A (HIP/PAP) therapeutic delivered through a proprietary AAV gene-therapy platform, championed by Prof. Christian Bréchot
Tampa, Fla., and Paris, France, August 17, 2026 — The Healthy Aging Company (THAC) has appointed Modulus Biotech as its exclusive worldwide partnering and licensing representative for ALF5755, a first-in-class REG3A (HIP/PAP) therapeutic delivered through a proprietary AAV gene-therapy platform for durable in-vivo expression. On THAC's behalf, Modulus Biotech will identify, negotiate, and manage co-development, licensing, and related commercial partnerships for ALF5755 across five indication areas, worldwide.
About ALF5755
ALF5755 is a first-in-class therapeutic based on REG3A (HIP/PAP), a novel extracellular antioxidant that captures reactive oxygen species, acting on a shared disease biology of insulin resistance, oxidative stress, tissue repair, and gut-microbiome disruption. THAC's go-forward product delivers REG3A through a proprietary AAV gene-therapy platform designed for durable in-vivo expression; completed recombinant-protein Phase 1 and Phase 2a clinical studies (NCT01318525) established a human safety and pharmacokinetic profile. ALF5755 builds on foundational research from leading French institutions (INSERM, AP-HP, INRA, University of Paris). THAC owns the resulting patent estate, with the exception of the patents covering cognitive disorders and the liver and AAV-REG3A provisional, which are shared with the University of South Florida under exclusive license. In the Phase 2a study (NCT01318525), while the primary endpoint was not met in the overall population, in pre-specified subgroup analyses by hepatitis etiology, patients with HBV- or autoimmune-hepatitis-related severe acute hepatitis showed a statistically significant improvement in coagulation-protein synthesis and shorter hospitalization; the program is advancing toward confirmatory, efficacy-stage evaluation in that population.
The five indication areas are:
- Acute Liver Failure (ALF): a rare, life-threatening condition; orphan-eligible.
- Acute-on-Chronic Liver Failure (ACLF): a high-mortality condition with no approved disease-modifying therapy.
- Type 2 Diabetes Mellitus (T2DM), including diabetic neuropathy: supported by existing method-of-use intellectual property, with a regulatory foundation established for the neuropathy indication.
- Alzheimer's Disease (AD): a non-amyloid mechanism, complementary to approved therapies.
- Traumatic Brain Injury (TBI): a growing medical concern with no efficient therapy, supported by an existing method-of-use (neuroprotection) patent family.
Scientific Leadership, Professor Christian Bréchot
The ALF5755 program is championed by Professor Christian Bréchot, one of the world's foremost authorities on viral hepatitis and liver disease, and a scientist with a direct connection to the foundational biology of ALF5755.
Professor Bréchot is Founder & Chairman of THAC and, based in the United States, a Professor at the University of South Florida, a scientist of international standing. He is President Emeritus of the Global Virus Network (GVN); the former President of the Institut Pasteur (2013 to 2017); and the former President of INSERM, France's national institute for health and medical research (2001 to 2007). He was recently elected a Fellow of the American Academy of Microbiology and of the National Academy of Inventors.
Most notably for ALF5755, Professor Bréchot's group at the Centre Hépato-Biliaire explored the HIP/PAP molecule that is the basis of ALF5755, demonstrating its highly original mechanism of action, and, in peer-reviewed work (Hepatology, 2011), that HIP/PAP protects against and reverses acute liver injury in vivo.
About The Healthy Aging Company (THAC)
The Healthy Aging Company is a biopharmaceutical company based in the United States, at the University of South Florida, and in Paris, developing ALF5755, a first-in-class REG3A (HIP/PAP)-based therapeutic delivered through a proprietary AAV gene-therapy platform, for serious conditions driven by oxidative stress and microbiome disruption.
Modulus Biotech's Mandate
As THAC's exclusive partnering and licensing representative, Modulus Biotech will lead partnering strategy and execution, beginning with the liver indications (ALF and ACLF) where the program is most advanced.
About Modulus Biotech
Modulus Biotech is a U.S.-based biopharmaceutical business-development firm providing exclusive scientific representation to innovators, with a focus on rare and serious diseases. Modulus Biotech, 177 E. Saddle River Road, PO Box 689, Saddle River, NJ 07458.
Media / Partnering Contact
Modulus Biotech · press@modulusbiotech.ai
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of applicable securities laws. ALF5755 is an investigational product; it has not been approved by the FDA, the EMA, or any other regulatory authority, and its safety and efficacy have not been established. In the Phase 2a study (NCT01318525), ALF5755 did not meet the primary efficacy endpoint in the overall intent-to-treat population; although it did not succeed in the whole group, it did improve outcomes in the subgroup of patients with HBV- or autoimmune-hepatitis-related severe acute hepatitis, the more severely ill patients, where treatment produced a statistically significant improvement in coagulation-protein synthesis and a significant reduction in length of hospitalization. These subgroup analyses by hepatitis etiology were pre-specified in the study's statistical analysis plan; the combined presentation is a permitted post-hoc pooling reported with nominal p-values. These findings do not establish efficacy and require confirmation in adequately powered prospective trials. References to de-risking relate to the program's established human safety and pharmacokinetic profile, its intellectual-property estate, and its regulatory groundwork, and not to demonstrated efficacy. The five indication areas are development targets, not approved uses, and there can be no assurance that any future clinical study will meet its endpoints, that any regulatory filing will be accepted or approved, or that any partnership will be concluded on the terms described, if at all. Statements regarding intellectual property and regulatory pathways reflect current understanding and require independent verification. This announcement does not constitute an offer to sell or a solicitation of an offer to buy any securities.